Logo

TELO

Telomir Pharmaceuticals, Inc. Common Stock

TELO

Telomir Pharmaceuticals, Inc. Common Stock • NASDAQ
$1.34 ▲ 1.52% (+0.02)
Market Cap $46.07 M
52w High $7.08
52w Low $1.12
Dividend Yield 0%
P/E -3.62
Volume 311.52K
Outstanding Shares 34.38M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.146M ▼ $-1.102M ▲ 0% $-0.034 ▲ $-1.1M ▲
Q2-2025 $0 $5.07M ▲ $-5.07M ▼ 0% $-0.17 ▼ $-5.069M ▼
Q1-2025 $0 $2.188M ▼ $-2.18M ▲ 0% $-0.073 ▲ $-2.18M ▲
Q4-2024 $0 $2.905M ▼ $-2.898M ▲ 0% $-0.098 ▲ $-2.898M ▲
Q3-2024 $0 $6.006M $-5.991M 0% $-0.2 $-5.991M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.329M ▲ $7.402M ▲ $422.807K ▲ $6.979M ▲
Q2-2025 $754.323K ▲ $829.611K ▲ $348.388K ▼ $481.223K ▲
Q1-2025 $402.999K ▼ $491.188K ▼ $652.294K ▼ $-161.106K ▼
Q4-2024 $1.266M ▲ $1.324M ▲ $680.968K ▲ $643.037K ▲
Q3-2024 $834.638K $1.042M $599.911K $442.074K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.102M ▲ $-927.265K ▼ $0 $7.502M ▲ $6.575M ▲ $-927.26K ▼
Q2-2025 $-5.07M ▼ $-696.444K ▲ $0 $1.048M ▲ $351.324K ▲ $-696.44K ▲
Q1-2025 $-2.18M ▲ $-863.132K ▼ $0 $0 ▼ $-863.132K ▼ $-863.132K ▼
Q4-2024 $-2.898M ▲ $-605.808K ▲ $0 $1.037M ▲ $431.493K ▲ $-605.81K ▲
Q3-2024 $-5.931M $-1.002M $0 $-46.909K $-1.049M $-1.002M

Five-Year Company Overview

Income Statement

Income Statement Telomir is a classic pre‑revenue biotech story. The company does not yet generate product sales, and its income statement is driven almost entirely by research and development spending and general corporate costs. Losses have been relatively small in absolute terms but are steadily widening as the company ramps up its activities. This pattern is normal for a preclinical biotech: spending first on science, people, and regulatory work, with the hope of revenue much later if products succeed. The key point is that the business is currently an R&D engine, not an operating company with recurring income.

Balance Sheet

Balance Sheet The reported balance sheet data are sparse, but available commentary suggests a structure typical of an early-stage biotech: assets are largely cash and research-related items, funded mostly by equity rather than debt. The absence of meaningful borrowings reduces financial leverage risk, but it also means the company is dependent on raising new capital over time to fund trials and operations. As with many young biotechs, the real “assets” are its drug candidates and intellectual property rather than physical property or large working capital balances.

Cash Flow

Cash Flow Cash flows are negative and driven by operating needs: research work, preclinical studies, and overhead. There is essentially no spending on heavy equipment or facilities, which keeps capital expenditure low, but that does not change the fact that the business consumes cash rather than generates it. Future progress will likely depend on periodic fundraising events, partnerships, or licensing deals. The central cash-flow question for observers is whether the existing cash cushion and any potential new capital can carry the company through its planned milestones and into early clinical data readouts.

Competitive Edge

Competitive Edge Telomir sits in a highly crowded but still emerging longevity and age‑related disease space. Its lead program, Telomir‑1, aims to differentiate itself through a multi‑pronged mechanism: targeting telomeres, metal ion balance, and epigenetic changes all at once. This breadth gives it a distinctive scientific profile versus peers who focus on just one aging pathway. The company is also working to secure broad intellectual property rights around its lead asset, which, if granted and defended, could form a meaningful barrier to direct copycats. However, Telomir still competes indirectly with far larger pharmaceutical and biotech companies pursuing their own approaches to aging, oncology, and metabolic disease, many of which have deeper resources, more advanced pipelines, and established commercial footprints. Telomir’s competitive position therefore rests on the strength of its science and IP rather than on scale or market presence at this stage.

Innovation and R&D

Innovation and R&D Innovation is the core of Telomir’s story. The company is pursuing an ambitious concept: using a single, orally available molecule to influence telomere length, cellular metal balance, and epigenetic aging markers. Early preclinical data suggest broad potential across age‑related disorders, rare premature-aging syndromes, metabolic disease, and even certain cancers, plus a separate antibacterial program leveraging its metal‑binding chemistry. The pipeline is still preclinical, so the scientific and regulatory risks are very high, and it is far from proven that the encouraging laboratory results will translate into safe, effective human medicines. A notable feature of the strategy is the planned veterinary indication in dogs as a faster route to real‑world data and earlier potential revenue. Overall, Telomir is research‑heavy, science‑driven, and still at an early point on the R&D risk curve.

Summary

Telomir Pharmaceuticals is an early‑stage biotech focused on a bold approach to aging and age‑related disease, with no commercial products and no current revenue. Financially, it operates like a typical preclinical company: modest but growing losses, cash as the key resource, and a need for ongoing external funding. Its balance sheet appears relatively simple and largely equity‑financed, which limits debt risk but heightens dependence on capital markets and partnering. The company’s potential value is tied almost entirely to the success of its science—especially Telomir‑1 and its associated intellectual property. If the multi‑pathway aging concept works in humans, the addressable opportunities are large; if it does not, the downside is equally significant because there is no existing business to fall back on. The next several years of clinical and veterinary data, plus the company’s ability to finance those efforts, will be critical in determining how this story evolves.

NEWS

November 25, 2025 · 8:00 AM UTC

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Read more

November 21, 2025 · 7:30 AM UTC

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Read more

November 12, 2025 · 8:00 AM UTC

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

Read more

October 23, 2025 · 7:30 AM UTC

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

Read more

October 21, 2025 · 7:30 AM UTC

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Read more